Previous 10 | Next 10 |
Repare Therapeutics (NASDAQ:RPTX) is continuing to benefit Thursday from a licensing deal with Roche (OTCQX:RHHBY) announced after the closing bell Wednesday. In afternoon trading, shares are up ~40%. Under the terms, Repare (RPTX) is receiving $125M in upfront payments and up to $1.2 bi...
After the market closed Wednesday, Repare Therapeutics (NASDAQ: RPTX) announced that it had entered into a licensing and collaboration deal with Roche (OTC: RHHBY) for its experimental cancer drug, camonsertib, also known as RP-3500. In the wake of that news, Repare shares s...
Gainers: Immix Biopharma (IMMX) +37%. Bright Green (BGXX) +29%. Repare Therapeutics (RPTX) +29%. Yumanity Therapeutics (YMTX) +24%. PDS Biotechnology (PDSB) +15%. Losers: Zosano Pharma (ZSAN) -48%. Immunic (IMUX) -41%. Aeglea BioTherapeutics (AGLE) -40%...
Repare Therapeutics (NASDAQ:RPTX) climbed ~17% in the post-market Wednesday after the clinical-stage precision oncology company announced a worldwide license and collaboration agreement with Swiss pharma giant Roche (OTCQX:RHHBY) (OTCQX:RHHBF) for its leading cancer candidate RP-350...
Repare will receive a $125 million upfront payment and is eligible to receive up to an additional $1.2 billion in potential development, regulatory, commercial and sales milestones, plus royalties on global net product sales Repare to host conference call today at ...
Repair Therapeutics (RPTX) shares trade higher after the 10% owner bought 420,000 shares at $8.50 worth ~$3.6M. Stock is up 9% in mid-day trading session. For further details see: Repair Therapeutics jumps 9% after $3.6M insider buying
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the virtual 2022 Guggenheim Synthetic L...
Repare Therapeutics press release (NASDAQ:RPTX): Q1 GAAP EPS of -$0.83 beats by $0.04. Revenue of $0.41M (+141.2% Y/Y) misses by $1.55M. For further details see: Repare Therapeutics GAAP EPS of -$0.83 beats by $0.04, revenue of $0.41M misses by $1.55M
Oral presentation of clinical data from the Phase 1/2 TRESR Trial of camonsertib (also known as RP-3500) monotherapy in solid tumors at 2022 AACR Annual Meeting Results demonstrated robust activity in ovarian cancer with a 75% CBR, 25% ORR and 35 weeks mPFS Results als...
Data show PKMYT1 inhibition is a promising therapeutic target in CCNE1-amplified cancers RP-6306, a first-in-class, oral PKMYT1 inhibitor, is currently being evaluated in Phase 1 clinical trials Repare Therapeutics Inc. (“Repare” or the “Company&...
News, Short Squeeze, Breakout and More Instantly...
Repare Therapeutics Inc. Company Name:
RPTX Stock Symbol:
NASDAQ Market:
Repare Therapeutics Inc. Website:
Alberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fund Canada NewsWire AEC invests US$7.5M into Amplitude Ventures US$192M Fund II to support the growth of life science startups, establishing a full-time Amplitude presence in ...
Overall response of 18.2% in heavily pretreated patients across gastrointestinal tumors with target alterations regardless of prior irinotecan exposure Prolonged clinical benefit in patients with CRC, with 40% of irinotecan-naïve patients receiving treatment for greater than nine mon...
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s camonsertib monotherapy non-small cell lung cancer (NSCLC) expansion of th...